Anticancer activity of oncolytic adenoviruses carrying p53 is augmented by 11R in gallbladder cancer cell lines in vitro and in vivo

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 833-841

  Wang, Jinghan ^a   Yu, Yong ^a   Yan, Zi ^a   Hu, Zhenli ^b   Li, Linfang ^a   Li, Jiang ^a   Jiang, Xiaoqing ^a   Qian, Qijun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

11R; Cell penetrating peptide; Gallbladder cancer; Gene therapy; p53

Indexed keywords

ADENOVIRUS VECTOR; CELL PENETRATING PEPTIDE; PROTEIN P53;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; FIBROBLAST; GALLBLADDER CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; P53 GENE; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; FIBROBLASTS; GALLBLADDER NEOPLASMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879658274     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2511     Document Type: Article

References (40)

1. Yalcin S: Diagnosis and management of cholangiocarcinomas: a comprehensive review. Hepatogastroenterology 51: 43-50, 2004.
2. Artem'eva NN and Burygina LV: Cancer of the gallbladder. Vestn Khir Im I I Grek 115: 35-40, 1975 (In Russian).
3. Malik IA: Gallbladder cancer: current status. Expert Opin Pharmacother 5: 1271-1277, 2004.
4. Henson DE, Albores-Saavedra J and Corle D: Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer 70: 1493-1497, 1992.
5. Lersch C and Classen M: Palliative therapy of carcinomas of the biliary system. Med Klin 92: 401-405, 1997 (In German). (Pubitemid 27346751)
6. Verma IM and Somia N: Gene therapy - promises, problems and prospects. Nature 389: 239-242, 1997. (Pubitemid 27406627)
7. Greco O, Scott SD, Marples B and Dachs GU: Cancer gene therapy: 'delivery, delivery, delivery'. Front Biosci 7: d1516-d1524, 2002.
8. Lowe SW, Cepero E and Evan G: Intrinsic tumour suppression. Nature 432: 307-315, 2004. (Pubitemid 39551658)
9. Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283, 2007. (Pubitemid 46474662)
10. Tomasini R, Mak TW and Melino G: The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 18: 244-252, 2008.
11. Baek JH, Agarwal ML, Tubbs RR, et al: In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer. J Korean Med Sci 19: 834-841, 2004. (Pubitemid 40104876)
12. Bookstein R, Demers W, Gregory R, Maneval D, Park J and Wills K: p53 gene therapy in vivo of hepatocellular and liver metastatic colorectal cancer. Semin Oncol 23: 66-77, 1996. (Pubitemid 26087990)
13. Inoue H, Shiraki K, Murata K, et al: Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Int J Mol Med 14: 271-275, 2004.
14. Shimada H, Shimizu T, Ochiai T, et al: Preclinical study of adenoviral p53 gene therapy for esophageal cancer. Surg Today 31: 597-604, 2001. (Pubitemid 32695785)
15. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ and Roth JA: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2: 1665-1671, 1996. (Pubitemid 26356349)
16. Lu YH, Wang K, He R and Xi T: Knockdown of survivin and upregulation of p53 gene expression by small interfering RNA induces apoptosis in human gastric carcinoma cell line SGC-823. Cancer Biother Radiopharm 23: 727-734, 2008.
17. Carroll JL, Michael Mathis J, Bell MC and Santoso JT: p53 Adenovirus as gene therapy for ovarian cancer. Methods Mol Med 39: 783-792, 2001.
18. Koom WS, Park SY, Kim W, et al: Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma. J Radiat Res 53: 202-210, 2012.
19. Roa I, Melo A, Roa J, Araya J, Villaseca M and de Aretxabala X: P53 gene mutation in gallbladder cancer. Rev Med Chil 128: 251-258, 2000 (In Spanish).
20. Takagi S, Naito E, Yamanouchi H, Ohtsuka H, Kominami R and Yamamoto M: Mutation of the p53 gene in gallbladder cancer. Tohoku J Exp Med 172: 283-289, 1994.
21. Kasuya K, Nagakawa Y, Matsudo T, et al: p53 gene mutation and p53 protein overexpression in a patient with simultaneous double cancer of the gallbladder and bile duct associated with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 16: 376-381, 2009.
22. Lehto T, Simonson OE, Mager I, et al: A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther 19: 1457-1467, 2011.
23. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH and Wender PA: Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci USA 105: 12128-12133, 2008.
24. Rothbard JB, Garlington S, Lin Q, et al: Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6: 1253-1257, 2000.
25. Lindgren M, Rosenthal-Aizman K, Saar K, et al: Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol 71: 416-425, 2006. (Pubitemid 43077076)
26. Takenobu T, Tomizawa K, Matsushita M, et al: Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 1: 1043-1049, 2002.
27. Inoue M, Tomizawa K, Matsushita M, et al: p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells. Eur Urol 49: 161-168, 2006. (Pubitemid 41789974)
28. Michiue H, Tomizawa K, Matsushita M, et al: Ubiquitination-resistant p53 protein transduction therapy facilitates anti-cancer effect on the growth of human malignant glioma cells. FEBS Lett 579: 3965-3969, 2005. (Pubitemid 40961896)
29. Wang JH, Li LF, Yu Y, et al: Establishment and characterization of a cell line, EH-GB2, derived from hepatic metastasis of gallbladder cancer. Oncol Rep 27: 775-782, 2012.
30. Li LF, Hu HZ, Liu C, et al: Establishment and characterization of a human gallbladder carcinoma cell line EH-GB1 originated from a metastatic tumor. Zhonghua Zhong Liu Za Zhi 32: 84-87, 2010 (In Chinese).
31. Maguire AM, High KA, Auricchio A, et al: Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374: 1597-1605, 2009.
32. Cideciyan AV, Hauswirth WW, Aleman TS, et al: Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 361: 725-727, 2009.
33. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al: Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823, 2009.
34. Christine CW, Starr PA, Larson PS, et al: Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73: 1662-1669, 2009.
35. Lees AJ, Hardy J and Revesz T: Parkinson's disease. Lancet 373: 2055-2066, 2009.
36. Rubnitz JE, Gibson B and Smith FO: Acute myeloid leukemia. Hematol Oncol Clin North Am 24: 35-63, 2010.
37. Goldin RD and Roa JC: Gallbladder cancer: a morphological and molecular update. Histopathology 55: 218-229, 2009.
38. Guan YS, La Z, Yang L, He Q and Li P: p53 gene in treatment of hepatic carcinoma: status quo. World J Gastroenterol 13: 985-992, 2007. (Pubitemid 46510997)
39. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991. (Pubitemid 21896613)
40. Yu ZW, Zhao P, Liu M, et al: Reversal of 5-fluorouracil resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells. World J Gastroenterol 10: 1979-1983, 2004. (Pubitemid 39029307) Projects of Prevention and Treatment of Major Infectious Diseases